We invest exclusively in healthtech companies that are transforming healthcare delivery, improving patient outcomes, and creating lasting value. Healthcare innovation is no longer limited to the lab—it's now in the cloud, the clinic, and the home.
Healthcare is undergoing a fundamental transformation driven by non-discretionary structural forces. Global healthcare spending is estimated to exceed $11 trillion in 2025, representing over 10% of global GDP. This massive scale is driven by aging populations, chronic disease prevalence, and clinician shortages—creating exceptional investment stability compared with cyclical sectors.
The demographic imperatives are both clear and irreversible. The global population aged 65 and above is set to double by 2050, while chronic diseases now account for 73% of global deaths. Simultaneously, healthcare systems face a projected clinician shortage exceeding 10 million professionals by 2030, creating urgent demand for technology-enabled solutions that can scale care delivery efficiently.
What distinguishes the current investment moment is the convergence of mature enabling technologies with innovation-friendly regulatory environments. AI is collapsing the clinical timeline, turning previously uncertain 10-year cycles into 3-year commercializable realities. Where AI meets robotics, precision meets automation—this intersection is the most investable layer of modern healthcare.
Telemedicine, remote patient monitoring, digital therapeutics, and consumer health applications. The remote care and digital therapeutics segments have validated their commercial viability with clear reimbursement pathways and major exits through both public markets and strategic acquisitions.
AI-powered robotics for automated clinical workflows. Companies in surgery and fertility automation have demonstrated how robotics can simultaneously improve patient outcomes and automate labor-intensive processes, creating compelling value propositions for healthcare systems under cost pressure.
Electronic health records, data interoperability, analytics platforms, and infrastructure that powers modern healthcare. Capital-efficient, lower-risk verticals delivering faster commercialization and broader impact.
Over 900 AI-enabled medical devices cleared by the FDA as of 2025, spanning radiology, cardiology, and pathology. The maturation of AI diagnostics exemplifies the transformation—what once required years of manual analysis can now be automated in real-time.
New models of care delivery, value-based care platforms, and solutions addressing fundamental market needs rather than creating new demand. This results in more predictable adoption curves and sustainable competitive advantages once market penetration is achieved.
Technologies benefiting from FDA Breakthrough Devices Program, European Innovation Council support, and advanced reimbursement frameworks. When the tech is ready and the regulators are too, returns don't wait a decade.
We invest in companies with robust clinical validation and clear paths to commercialization or exit. Late-venture or early-growth stage entry points offer asymmetric upside with greater downside protection.
Solutions that demonstrably improve patient outcomes, reduce costs, or expand access to quality care. Healthtech companies address fundamental market needs, resulting in more predictable adoption and sustainable advantages.
Technologies with FDA approval, CE-MDR clearance, or strong reimbursement positioning. Regulatory expertise creates natural advantages—complexity becomes a strategic asset rather than a liability.
Innovative platforms that can scale efficiently while maintaining quality and compliance. The convergence of AI, cloud infrastructure, and genomics has reached sufficient maturity to solve long-standing clinical pain points.
The investment implications are profound: healthtech companies are addressing fundamental market needs rather than creating new demand, resulting in more predictable adoption curves and sustainable competitive advantages once market penetration is achieved.
Non-discretionary drivers create durable, macro-insulated demand. Sickness doesn't follow market cycles.
Robust M&A activity and returning IPO appetite. Exits rely on need, not sentiment.